Abstract: Tendon and ligament injuries in equine athletes pose significant challenges, often leading to prolonged recovery, reduced performance, and increased risk of reinjury. Current treatment strategies, including conservative and surgical approaches, have shown limited success in fully restoring tendon integrity. Autologous blood derivatives, such as autologous conditioned serum (ACS), have emerged as potential regenerative therapies. However, the clinical efficacy of ACS in the treatment of equine tendinopathies remains under investigation. Unassigned: This study aimed to compare the clinical outcomes between intralesional ACS injections and conservative treatment in horses diagnosed with superficial digital flexor tendon (SDFT), deep digital flexor tendon (DDFT), and suspensory ligament (SL) injuries. Unassigned: This retrospective observational case-control study used clinical data from 100 horses evaluated for lameness between 2017 and 2022. Horses were categorized into two groups: the IRAP group ( = 48), which received three intralesional ACS injections at 1-week intervals, and the NO-IRAP group ( = 52), which was treated conservatively with NSAIDs and a structured rehabilitation program. Lameness assessments and ultrasonographic evaluations were performed at initial presentation and follow-up at 4, 8, and 12 weeks. The statistical analyses compared changes in lameness scores between the two groups. Unassigned: At 4 weeks, improvement in lameness was observed in 51.5% and 55.6% of the IRAP and NO-IRAP groups, respectively. At 8 weeks, improvement rates were 47% and 42.2%, respectively. By 12 weeks, 60.7% of the IRAP group and 55% of the NO-IRAP group showed improvement. However, a subset of horses in the IRAP group experienced transient worsening of lameness (8.5%-17.7%). Stratification by lesion type revealed better outcomes in the IRAP group for SDFT (58.3% 48%) and SL (51.2% 36%) injuries, whereas the NO-IRAP group had superior results for DDFT injuries (60.9% 46.2%). Unassigned: The study suggests that ACS treatment enhances tendon and ligament healing, particularly in SDFT and SL injuries. However, the transient worsening of lameness observed in some horses receiving ACS warrants further investigation. Although these findings support the potential benefits of ACS, controlled randomized clinical trials are needed to validate its efficacy and optimize treatment protocols for equine tendon and ligament pathologies.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
Overview
This study evaluated the effectiveness of autologous conditioned serum (ACS), delivered via intralesional injections, compared to conservative treatment for tendon and ligament injuries in horses.
The research focused on equine superficial digital flexor tendon (SDFT), deep digital flexor tendon (DDFT), and suspensory ligament (SL) injuries, analyzing clinical outcomes from 100 cases over a 12-week period.
Background and Rationale
Tendon and ligament injuries are common and challenging issues in equine athletes, often causing long recovery times and diminished performance.
Traditional treatments include conservative care (like NSAIDs and rehabilitation) and surgical repair, but these often fail to fully restore the tendon or ligament to its original state.
Autologous conditioned serum (ACS), a blood derivative enriched with anti-inflammatory and regenerative factors, has been proposed as a novel treatment option to promote healing, but its clinical effectiveness is not fully established.
Study Design and Methods
This was a retrospective observational case-control study using clinical records from 100 horses treated between 2017 and 2022.
Horses were divided into two groups:
IRAP group (n=48): Received three ACS intralesional injections spaced one week apart.
NO-IRAP group (n=52): Received conservative treatment consisting of non-steroidal anti-inflammatory drugs (NSAIDs) and a structured rehabilitation protocol.
Lameness scoring and ultrasound evaluations were performed at baseline and then at 4, 8, and 12 weeks to monitor progress.
The primary outcome measure was improvement in lameness scores over time, compared between the two groups.
Results
At 4 weeks:
51.5% of horses treated with ACS showed improvement in lameness.
55.6% of horses under conservative treatment improved.
At 8 weeks:
47% improvement rate in the ACS group.
42.2% improvement in the NO-IRAP group.
At 12 weeks:
60.7% of ACS-treated horses improved.
55% of those treated conservatively improved.
Some horses in the ACS group experienced a temporary worsening of lameness symptoms, ranging from 8.5% to 17.7% depending on timepoints.
When accounting for injury type:
ACS treatment showed better outcomes for SDFT injuries (58.3% improved vs. 48% in controls) and suspensory ligament injuries (51.2% vs. 36%).
Conservative treatment was more effective for DDFT injuries (60.9% improved vs. 46.2% with ACS).
Interpretation and Implications
The findings suggest that ACS may enhance healing particularly for superficial digital flexor tendon and suspensory ligament injuries.
The greater improvement in these injuries might be due to the biological effects of ACS in reducing inflammation and promoting tissue regeneration.
The transient lameness worsening in some horses receiving ACS could indicate an initial inflammatory reaction or other side effects that require further study.
The study’s observational and retrospective design limits the strength of conclusions; randomized controlled trials are needed to confirm the benefits and refine treatment protocols.
Results contribute to the growing evidence supporting autologous blood products as adjunct therapies in equine tendon and ligament repair.
Conclusion
Autologous conditioned serum shows promise as a treatment to improve healing outcomes in certain equine tendon and ligament injuries.
Clinical benefits were particularly notable for SDFT and suspensory ligament lesions, while conservative treatment sometimes performed better for DDFT injuries.
Future prospective and randomized studies are necessary to validate these results, understand the cause of transient worsening, and optimize ACS application in veterinary sports medicine.
Cite This Article
APA
Tommasa SD, Raspe S, Farí G, Imperante A, Brehm W.
(2025).
Autologous conditioned serum IRAP efficacy for tendon and ligament injuries in horses: An observational study.
Open Vet J, 15(8), 3787-3793.
https://doi.org/10.5455/OVJ.2025.v15.i8.43
Baxter GM. Tendon and ligament injuries and disease. In: Baxter GM, editor. In Adams and Stashak’s Lameness in Horses. Chichester, FL: Wiley-Blackwell; 2012. pp. 927–938.
Carvalho AM, Badial PR, Álvarez LE, Yamada AL, Borges AS, Deffune E, Hussni CA, Garcia, Alves AL. Equine tendonitis therapy using mesenchymal stem cells and platelet concentrate: a randomized controlled trial. Stem Cell Res. Ther. 2013;4:85.
Dahlgren LA, Harvey SC. Effect of autologous conditioned serum on the metabolism of normal tendon explants. In: 54th Annual Meeting of the Orthopedic Research Society; March 2–5, 2019. Rosemont, IL: Orthopedic Research Society; 2008.
Dakin SG, Dudhia J, Smith RKW. Modulation of prostaglandin E2 production in equine tendon cells. In: 49th British Equine Veterinary Association Congress; September 8–11. Newmarket, England: Equine Veterinary Journal, Ltd; 2010. p. 96.
Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intraarticular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am. J. Vet. Res. 2007;68:290–6.
Ionita JC, Brehm W. Autologe Blutprodukte in der Regenerativen Therapie: ACS, PRP, ACP, Knochenmark (Autologous blood products for regenerative therapies: ACS, PRP, ACP, bone marrow). In: Lauk HD, editor. In Pferdeheilkunde Forum-Berliner Fortbildungstage. Berlin, Germany: Hippiatrika Verlag; 2008. pp. 588–591.
James R, Kesturu G, Balian G, Chhabra AB. Tendon: biology, biomechanics, repair, growth factors, and evolving treatment options. J. Hand Surg. Am. 2008;33:102–112.
Jann H, Stashak TS. Tendon and Paratendon Lacerations. In: Stashak TS, Theoret CL, editors. In Equine wound management. Ames, Iowa: Wiley-Blackwell; 2008. pp. 489–508.
Lam KH, Parkin TDH, Riggs CM, Morgan KL. Descriptive analysis of the retirement of Thoroughbred racehorses due to tendon injuries at the Hong Kong Jockey Club (1992-2004). Equine Vet. J. 2007;39:143–148.
Majewski M, Ochsner PE, Liu F, Fluckiger R, Evans CH. Accelerated healing of the Achilles tendon in response to autologous conditioned serum. Am. J. Sports Med. 2009;37:2117–2125.
Murray RC, Dyson SJ, Tranquille C, Adams V. Association between sport type and performance level and anatomical site of orthopedic injury diagnosis. Equine Vet. J. 2006;36:411–416.
O’meara B, Bladon B, Parkin TDH, Fraser B, Lischer CJ. Investigation of the relationship between race performance and superficial digital flexor tendonitis in the Thoroughbred racehorse. Equine Vet. J. 2010;42:322–6.
Patterson-Kane JC, Firth EC. Pathobiology of exercise-induced superficial digital flexor tendon injury in Thoroughbred racehorses. Vet. J. 2009;181:79–89.
Sun HB, Li Y, Fung DT, Majeska RJ, Schaffler MB, Flatow EL. Coordinate regulation of IL-1beta and MMP-13 in rat tendons following subculture fatigue damage. Clin. Orthop. Relat. Res. 2008;466:1555–1561.
Textor J. Autologous biologic treatment of equine musculoskeletal injuries: a platelet-rich plasma and IL-1 receptor antagonist protein. Vet. Clin. North Am. Equine Pract. 2011;27:275–298.